Processing

Please wait...

Settings

Settings

1. WO2020033971 - USE OF IGF-2 RECEPTOR AGONIST LIGANDS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM

Publication Number WO/2020/033971
Publication Date 13.02.2020
International Application No. PCT/US2019/046227
International Filing Date 12.08.2019
Chapter 2 Demand Filed 31.12.2019
IPC
A61K 31/70 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
C07K 14/65 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
575Hormones
65Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
A61P 25/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
Applicants
  • NEW YORK UNIVERSITY [US/US]; 70 Washington Square South New York, NY 10012, US
Inventors
  • ALBERINI, Cristina, Maria; US
  • TRAUNER, Dirk; US
  • ARP, Christopher, James; US
Agents
  • WATT, Rachel, S.; US
  • KADLE, Ranjana; US
  • ROMAN, Paul, J.; US
  • LOPINSKI, John, D.; US
  • DIMAIO, John, T. M.; US
Priority Data
62/717,37210.08.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) USE OF IGF-2 RECEPTOR AGONIST LIGANDS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM
(FR) UTILISATION DE LIGANDS AGONISTES DU RÉCEPTEUR DE L'IGF-2 POUR LE TRAITEMENT DU SYNDROME D'ANGELMAN ET DE L'AUTISME
Abstract
(EN)
Provided are methods for treatment of neurodevelopmental disorders, such as Angelman Syndrome and autism comprising administering to an individual a composition comprising an agonist ligand of IGF -2 receptor. The agonist ligand of IGF-2 receptor may be IGF -2, or mannose-6-phosphate or a derivative thereof. Compositions comprising mannose-6-phosphate derivatives are also disclosed.
(FR)
L'invention concerne des méthodes de traitement de troubles neurodéveloppementaux, tels que le syndrome d'Angelman et l'autisme, comprenant l'administration à un individu d'une composition comprenant un ligand agoniste du récepteur de l'IGF-2. Le ligand agoniste du récepteur de l'IGF-2 peut être l'IGF-2, ou le mannose-6-phosphate ou un dérivé de celui-ci. L'invention concerne également des compositions comprenant des dérivés de mannose-6-phosphate.
Latest bibliographic data on file with the International Bureau